Prophylactic Treatment of Migraine with Gamma-Linolenic and Alpha-Linolenic Acids

Cephalalgia ◽  
1997 ◽  
Vol 17 (2) ◽  
pp. 127-130 ◽  
Author(s):  
W Wagner ◽  
U Nootbaar-Wagner

Polyunsaturated fatty acids (PUFA) were administered to 168 patients over a period of 6 months in an open-label uncontrolled study. In 129 patient available for study, 86% experienced reduction in severity, frequency and duration of migraine attacks, 22% became free of migraine and more than 90% had reduced nausea and vomiting. Self-medication changed to simple analgesics in the majority except in 14% of patients without improvement.

2015 ◽  
Vol 14 (1) ◽  
pp. 4 ◽  
Author(s):  
Simone Schmidt ◽  
Janina Willers ◽  
Sabine Riecker ◽  
Katharina Möller ◽  
Jan Schuchardt ◽  
...  

Nutrients ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3384
Author(s):  
Richard Lindberg ◽  
Maria Lindqvist ◽  
Miles Trupp ◽  
Marie-Therese Vinnars ◽  
Malin L. Nording

Polyunsaturated fatty acids (PUFAs) have been studied in relation to pregnancy. However, there is limited knowledge on PUFAs and their metabolites in relation to hyperemesis gravidarum (HG), a pregnancy complication associated with nutritional deficiencies and excessive vomiting. In order to survey the field, a systematic review of the literature was performed, which also included nausea and vomiting of pregnancy (NVP) due to its close relationship with HG. In the very few published studies found, the main subjects of the research concerned free fatty acids (four records), lipid profiles (three records), and bioactive lipids (one article about prostaglandin E2 and one about endocannabinoids). The authors of these studies concluded that, although no cause-and-effect relationship can be established, HG is linked to increased sympathetic responsiveness, thermogenic activity and metabolic rate. In addition, NVP is linked to a metabolic perturbance (which lasts throughout pregnancy). The low number of retrieved records underlines the need for more research in the area of PUFAs and HG, especially with regard to the underlying mechanism for the detected effects, potentially involving growth differentiation factor 15 (GDF15) since evidence for GDF15 regulation of lipid metabolism and the role for GDF15 and its receptor in nausea and vomiting is emerging.


2020 ◽  
Vol 36 (2) ◽  
pp. 95-106
Author(s):  
Agnieszka M. Piróg-Balcerzak ◽  
Anna K. Bażyńska ◽  
Katarzyna Biernacka ◽  
Joanna Brągoszewska ◽  
Lidia Popek ◽  
...  

Objective. Omega–3 polyunsaturated fatty acids (PUFAs) were tested in adolescent depression and in several neurodevelopmental disorders with partial success. Anorexia nervosa (AN) is characterised by deficiencies in fatty food intake and frequent comorbidity, including depressive and cognitive symptoms. Thus supplementation with PUFAs may be beneficial in this group of patients. The aim of the study was to assess whether PUFAs as an add-on treatment is associated with better improvement of body mass index (BMI) and psychopathological symptoms than placebo in patients with AN. Method. 61 female adolescent inpatients with AN were randomly allocated to omega–3 PUFAs supplementation or placebo for 10 weeks. Patients also participated in the behavioural programme and eclectic psychotherapy (treatment as usual, TAU). At baseline and follow-up visits, patients’ BMI and psychopathology were assessed with Clinical Global Impression Scale (CGI), Patient Global Impression Scale (PGI), and Eating Attitude Test (EAT-26). Results. After 10 weeks, both groups showed improvement in all parameters. Improvement in CGI scores was observed greater in placebo vs. PUFA-s group (p = 0.015) while other differences were not statistically significant. Omega–3 PUFAs supplementation appears not to be effective as an add-on treatment in inpatient adolescent girls with anorexia nervosa. Conclusions. The results should be analysed with caution due to small sample size and heterogeneity in TAU. As the TAU turned out to be highly effective, additional therapeutic effect of PUFA might not be visible. Nevertheless, that does not explain the tendency for better improvement in the placebo group.


2013 ◽  
Author(s):  
Natalie Shepherd ◽  
Jager Cassandre De ◽  
Abe Kasonga ◽  
Sumari Marais ◽  
Yuko Tousen ◽  
...  

2017 ◽  
Vol 81 (1) ◽  
pp. 64-73
Author(s):  
L.S. Ovcharenko ◽  
◽  
T.V. Slutskaya ◽  
A.A. Vertegel ◽  
T.G. Andrienko ◽  
...  

2017 ◽  
Vol 0 (0) ◽  
pp. 0
Author(s):  
A. Ruiz-González ◽  
S. Debruyne ◽  
J. Jeyanathan ◽  
L. Vandaele ◽  
S. De Campeneere ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document